| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General Clinical Chemistry |
1 Institut National de la Santé et de la Recherche Médicale E0361, Pathologies du Système Nerveux: Recherche Épidémiologique et Clinique; Université Montpellier I. Hôpital La Colombière, Montpellier, France.
2 NVMC (Unité de Nutrition Vieillissement et Maladie Cardiovasculaires), UFR de Pharmacie, Joseph Fourrier, Grenoble, France.
3 Institut National de la Santé et de la Recherche Médicale U708, Neuroepidemiologie, GH Pitié Salpétrière, Paris, France.
4 Département de Biologie Intégrée, CHU de Grenoble, Grenoble, France.
aAddress correspondence to this author at: Institut National de la Santé et de la Recherche Médicale E0361, Hôpital La Colombière, 39, Ave. Charles Flahault, BP 34493, 34093 Montpellier Cedex 5, France. Fax 33-(0)4-99-614-579; e-mail akbaraly{at}montp.inserm.fr.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Methods: The EVA study was a 9-year longitudinal study with 6 periods of follow-up. During the 2-year period from 1991 to 1993 (EVA0), 1389 men and women born between 1922 and 1932 were recruited. The effects of plasma selenium at baseline on mortality were determined by Cox proportional hazards regression analysis, adjusting for the following variables: sociodemographic characteristics, dietary habits, health, and cognitive factors.
Results: During the 9-year follow-up, 101 study participants died. Baseline plasma selenium was higher in individuals who were alive at the end of follow-up [mean (SD), 1.10 (0.20) µmol/L] than in those who died during the follow-up [1.01 (0.20) µmol/L; P <10–4]. Mortality rates were significantly higher in individuals with low selenium [increments = 0.2 µmol/L; relative risk (RR) = 1.56 (95% confidence interval, 1.28–1.89)]. After we controlled for various potential confounding factors, this association remained significant [RR = 1.54 (1.25–1.88)]. When the underlying causes of death were considered, we found an association with cancer-related mortality [adjusted RR = 1.79 (1.32–2.44)].
Conclusions: Even if it is premature to present selenium as a longevity indicator in an elderly population, our results are in accordance those of large, interventional, randomized trials with selenium, which suggest that this essential trace element plays a role in health maintenance in aging individuals.
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The anticarcinogenic properties of selenium at high doses suggest a possible link between selenium deficiency and cancer (3). A recent metaanalysis of 14 randomized trials that studied whether antioxidant supplements may prevent gastrointestinal cancers reported that selenium might have a beneficial effect on the incidence of gastrointestinal cancers(5); however, prospective longitudinal studies(6)(7)(8), case–control studies(9)(10)(11), and one randomized interventional trial(12) investigating the relationship between selenium and cancer produced conflicting results.
Selenium may also protect against cardiovascular diseases via counteraction of lipid oxidation by glutathione peroxidase and reduction of platelet aggregation (13). Epidemiologic studies have shown conflicting results(6)(14)(15)(16). An animal study analyzed the role of selenium in fly mortality and showed that the survival rate of flies fed a diet deficient in selenium was one half that of flies fed a diet supplemented with optimal amounts of selenium(17).
The aim of the Etude du Vieillissement Artériel (EVA)1 study was to evaluate the relationships between cognitive decline (18), vascular disease(19), and oxidative stress in elderly individuals. Our team has shown previously that EVA participants with low selenium concentrations at baseline exhibited an increased risk of cognitive decline(18). With the aging population, it is essential to investigate antioxidant status as a potential predictive health factor. Among antioxidants, selenium is of particular interest because in Europe, selenium status, determined by selenium concentrations in serum or plasma(1) or by selenium intake(20)(21), is not adequate for optimal glutathione peroxidase, selenoprotein P, and immune functions(1)(2). Inadequate selenium status may reduce human life expectancy either by accelerating the aging process or by increasing vulnerability to various diseases. To further examine this hypothesis, we explored the relationship between baseline plasma selenium concentrations and mortality.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
data collection
Vital statistics and date and cause of death were collected throughout the 9 years of follow-up. For each of the EVA steps and at the end of the 9th and last year of study, the health status of individuals for whom we had no feedback were collected from town hall civil registries. The cause of death was determined with the help of both families and physicians.
sociodemographic and other variables at baseline
The questionnaire elicited information on standard demographic variables such as sex and age. Educational achievement was divided into 2 categories: no school or primary school (primary school) and high school or university (high school or beyond).
Information about medication use, smoking status, and alcohol consumption was obtained from a standardized questionnaire at baseline. Individuals were classified as current smokers, nonsmokers, or former smokers. Alcohol consumption was determined from the estimated typical amount of alcoholic beverages ingested weekly and expressed in milliliters of alcohol per day. From this information, 3 groups were identified: abstainers, consumers of <20 mL per day, and consumers of >20 mL per day. Individuals who took 3 or more medicines per day were considered high medication users.
health variables
At baseline, participant weight and height were measured, and the body mass index was calculated; a body mass index >29 kg/m2 defined obesity. Participants with plasma glucose 
7.80 mmol/L (1.40 g/L), those taking antidiabetic medications, or those reporting a history of diabetes were considered to have diabetes. Participants were considered to have dyslipidemia if they had a total cholesterol 2.80 g/L, used lipid-lowering drugs, or reported a history of dyslipidemia. Two independent measurements of systolic and diastolic blood pressure were made with a digital electronic tensiometer (SP9 Spengler) after a 10-min rest; the mean values were used in the analysis. Individuals with systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg, those using antihypertensive medications, and those reporting a medical history of hypertension were classified as hypertensive. Individuals who reported a history of myocardial infarction, angina pectoris, or stroke and those who used vascular drugs were classified as having a history of cardiovascular disease. The Mini Mental Status Examination (MMSE) was used for cognitive assessment. The MMSE includes 18 items that assess various cognitive skills, with scores ranging from 0 to 30 (24). The lowest cognitive functioning was defined by an MMSE score below the 25th percentile of MMSE score distribution, which corresponded to a MMSE cutoff score of 28.
plasma selenium evaluation
We determined serum selenium with electrothermal atomic absorption spectrometry (PerkinElmer; 5100) according to Arnaud et al. (25). A selenium electrodeless discharge lamp and a Zeeman longitudinal background correction were used. Serum diluted in a solution containing 0.1 mol/L nitric acid, 2 g/L Triton X-100, and matrix modifier was introduced onto the platform of a pyrolytic graphite furnace. Concentration was obtained with an addition calibration. Seronorm® trace element serum (Sero) was chosen as an internal quality control. The target value was 1.30 µmol/L, and the mean (SD) observed value was 1.22 (0.10) µmol/L. Imprecision (as the CV) varied from 1.4% (within-run; n = 20) to 8% (between-run; n = 22) at a concentration of 1.30 µmol/L. In addition, the laboratory participated in 2 interlaboratory comparison trials organized by the French Society for Clinical Biology (Nancy, France) and the "Centre de Toxicologie du Québec" (Sainte-Foy, Québec, Canada) with results within the range of acceptable values.
statistical analysis
Vital statistics, sex, education, smoking status, alcohol intake, medication use, obesity, and health variables were considered categorical variables. Participant age was considered a continuous variable. Plasma selenium at baseline followed a gaussian distribution. Plasma selenium was first analyzed as a continuous variable, with 0.2 µmol/L corresponding to 1 SD of selenium distribution. For the second analysis, we considered plasma selenium concentration by quartiles. The median (range) values for each quartile (Q) were as follows: 0.87 (0.18–0.95) µmol/L for Q1 (below the 25th percentile); 1.03 (0.96–1.09) µmol/L for Q2 (at or above the 25th to below the 50th percentile); 1.15 (1.10–1.21) µmol/L for Q3 (at or above the 50th to below the 75th percentile); and 1.32 (1.22–1.97) µmol/L for Q4 (75th percentile and above). Baseline characteristics of participants who died during the follow-up period and those who remained alive were compared with the Student t-test for continuous variables and the 
2 test for categorical variables. Correlations between plasma selenium and the other continuous variables were calculated with the Pearson correlation coefficient. Survival was analyzed with actuarial methods, and a log-rank test was used to compare survival rates of individuals in different plasma selenium quartiles. The effects of plasma selenium on mortality were determined by the Cox proportional hazard regression analysis adjusted for potential confounding variables. We verified the proportionality assumption by adding a time-dependent variable to the model (26). The results of the Cox multivariate regressions were expressed by relative risk (RR) with the 95% confidence interval. All interactions between plasma selenium and other variables were tested. Statistical analysis was performed with SAS software, Ver. 8.2 (SAS Institute.).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
). For 88.1% of the individuals who died, the cause of death was determined by the general practitioner. Cancer was the leading cause of death (n = 45; 44.5%), followed by cardiovascular diseases (n = 22; 21.8%). The main factors related to mortality were: sex (male), smoking (current and former smoker), alcohol intake, medication use, obesity, diabetes, hypertension, and cardiovascular diseases. Surprisingly, age, education, and dyslipidemia were not related to mortality. Mean concentrations of plasma selenium measured at EVA0 were significantly higher in surviving individuals [mean (SD), 1.10 (0.20) µmol/L [than in those who died [1.01 (0.20) µmol/L; P <10–4]. Survival bivariate analysis showed that the RR of mortality during the EVA follow-up increased significantly with a decrease in plasma selenium [selenium = 0.2 µmol/L; RR = 1.56 (95% confidence interval, 1.28–1.89); P <10–4]. Comparisons of survival distributions among quartiles of plasma selenium showed that mortality increased in subgroups with low plasma selenium concentrations (Fig. 1
).
|
|
At baseline, plasma selenium concentrations were not significantly different between men and women (P = 0.189) and were not correlated with age in either sex (r = –0.05; P = 0.09). Plasma selenium was significantly higher in individuals who were in the highest education category [1.08 (0.20) µmol/L for those with less education vs 1.11 (0.20) µmol/L for those with more education; P = 0.003]. No link was observed between selenium and smoking status, alcohol consumption, or medication use. Concerning health status, selenium concentrations were higher in individuals with dyslipidemia [1.07 (0.19) µmol/L for normolipidemic individuals vs 1.13 (0.21) µmol/L for dyslipidemic individuals; P <0.001] and lower in obese individuals [1.10 (0.20) µmol/L in nonobese individuals vs 1.04 (0.19) µmol/L in obese individuals; P <0.001]. For diabetes, hypertension, and cardiovascular diseases, no significant association was found. As shown previously (23), mean plasma selenium concentrations were significantly lower in individuals with the lowest cognitive function [1.07 (0.21) µmol/L] than in other individuals [1.11 (0.20) µmol/L; P = 0.002].
The complete multivariate Cox models, controlling for all factors, showed that a 0.2 µmol/L decrease in plasma selenium was significantly associated with a higher mortality risk [RR = 1.54 (1.25–1.88); P <10–4]. Among all other included factors, only sex, diabetes, and a history of cardiovascular disease remained significantly associated with mortality risk (Table 2
). When we analyzed plasma selenium by quartiles, we observed that individuals with plasma selenium concentrations in the 2 lowest quartiles (Q1 and Q2) had a significantly higher risk of mortality than individuals in the highest plasma selenium quartile [Q1 vs Q4: RR = 3.34 (1.71–6.53); P = 0.0004; Q2 vs Q4: RR = 2.49 (1.25–4.94); P = 0.009]. We found no significant association for individuals who had a plasma selenium concentration in Q3 compared with individuals in Q4 [Q3 vs Q4: RR = 1.67 (0.78–3.56); P = 0.18].
|
plasma selenium and causes of death
In the individuals who died from cancer (n = 45), the mean (SD) baseline plasma selenium concentration was 1.00 (0.22) µmol/L. The baseline plasma selenium concentration was 1.06 (0.20) µmol/L in individuals who died from vascular diseases (n = 22) and 0.97 (0.20) µmol/L in individuals who died from other causes.
Cox models indicated no significant association with cardiovascular diseases or with other causes of death. In contrast, bivariate Cox models showed a significant association between cancer-related mortality and low plasma selenium concentrations [increment = 0.2 µmol/L; RR = 1.61 (1.19–2.13); P = 0.001; Table 3
]. Analysis by quartile of plasma selenium showed that mortality risk increased significantly in individuals with plasma selenium in Q1 and Q2 compared with individuals with plasma selenium in Q4 [Q1 vs Q4: RR = 4.06 (1.51–10.92); P = 0.006; Q2 vs Q4: RR = 2.95 (1.06–8.18); P = 0.04]. Cancer-related mortality did not differ significantly between individuals who had plasma selenium concentrations in Q3 compared with those in Q4 [Q3 vs Q4: RR = 1.92 (0.63–5.86); P = 0.25]. The multivariate Cox model (Table 3
) confirmed the results of the bivariate Cox model, with the exception of smoking status. The RR of cancer-related mortality associated with plasma selenium decreases in increments of 0.2 µmol/L, adjusting for all factors, was 1.79 (1.32–2.44); P = 0.0002. In the medical history interview at baseline, 62 individuals self-reported a lifetime cancer history. The baseline plasma selenium in these individuals was 1.07 (0.23) µmol/L [not significantly different from other individuals (P = 0.3)]. Among the 45 individuals who died of cancer during the follow-up, 5 self-reported a history of cancer at baseline. Analysis gave similar results for all-cause mortality or cancer mortality when the 62 individuals who self-reported a lifetime cancer history were excluded.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The relationships that we observed between mortality and confounding factors such as sex (male), smoking, alcohol consumption, medication, obesity, diabetes, and vascular disease, but not age and dyslipidemia, suggest that the relationship between plasma selenium and mortality is not an artifact. Moreover, significant associations between selenium and mortality, taking into account the potential mortality risk factors, suggest an effect of selenium per se on mortality risk.
When considering the underlying causes of death, we found an association between plasma selenium concentration and cancer mortality. Our findings for selenium and cancer should be viewed with some caution, given that only 45 cancer deaths occurred and that different cancers often have different risk factors; however, our observations are in agreement with previous studies (6)(7)(10)(11)(12), despite controversy and debate over the protective effect of selenium against cancer(8). In the Health Professionals Follow-up Study, a reduction in cancer risk was associated with higher toenail selenium concentrations(7). In a large case–control study on breast cancer risk, a statistically significant preventive effect of quite high concentrations of plasma selenium was found in 278 cases and 135 controls(10). In the Linxian study, Mark et al.(11) found a significant inverse association between selenium and esophageal and gastric cardia cancer mortality [RR = 0.90 (0.83–0.97) and 0.87 (0.79–0.96), respectively]. In the Nutritional Prevention of Cancer Trials(12), the administration of selenium (200 µg/day for 4.5 years) induced a significant reduction in total cancer mortality [RR = 0.50 (0.31–0.80)], incidence of total cancer [0.63 (0.47–0.85)], and incidence of lung, colorectal, and prostate cancers.
In our study, 22 deaths related to cardiovascular disease were identified, limiting the interpretation of the nonsignificant relationship between selenium and cardiovascular mortality. No association between cardiovascular disease and selenium status has been reported in the Health Professionals Follow-up Study (15), but other studies have demonstrated that low serum selenium concentrations were significantly associated with deaths from heart disease(6)(16).
Our results suggest that plasma selenium could be an indicator of longevity in a preaging, independently living population not specifically at risk for cancer and cardiovascular diseases. Survival curves well illustrate that the relationship between plasma selenium and mortality was not restricted to the first years of follow-up but remained pertinent during the entire 9-year period. However, the mechanism of this potential relationship is still under debate. The determination of selenoproteins such as selenoprotein P, glutathione peroxidase at circulating or tissular concentrations (29), or selenium metabolites such as methylselenol(3) could help to clarify this mechanism.
In conclusion, our preliminary results reinforce the importance of adequate selenium status for health maintenance in an aging population. Even if it is premature to portray selenium as a longevity indicator, our data support those of large interventional randomized trials, which suggest that this essential trace element may play a role in health maintenance during the aging process.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  S.-K. Myung, Y. Kim, W. Ju, H. J. Choi, and W. K. Bae Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials Ann. Onc., July 21, 2009; (2009) mdp286v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ashton, L. Hooper, L. J Harvey, R. Hurst, A. Casgrain, and S. J Fairweather-Tait Methods of assessment of selenium status in humans: a systematic review Am. J. Clinical Nutrition, June 1, 2009; 89(6): 2025S - 2039S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bleys, A. Navas-Acien, M. Laclaustra, R. Pastor-Barriuso, A. Menke, J. Ordovas, S. Stranges, and E. Guallar Serum Selenium and Peripheral Arterial Disease: Results From the National Health and Nutrition Examination Survey, 2003-2004 Am. J. Epidemiol., April 15, 2009; 169(8): 996 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Akbaraly, A. Fontbonne, A. Favier, and C. Berr Plasma Carotenoids and Onset of Dysglycemia in an Elderly Population: Results of the Epidemiology of Vascular Ageing Study Diabetes Care, July 1, 2008; 31(7): 1355 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Meplan, L. K Crosley, F. Nicol, G. W Horgan, J. C Mathers, J. R Arthur, and J. E Hesketh Functional effects of a common single-nucleotide polymorphism (GPX4c718t) in the glutathione peroxidase 4 gene: interaction with sex Am. J. Clinical Nutrition, April 1, 2008; 87(4): 1019 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bleys, A. Navas-Acien, and E. Guallar Serum Selenium Levels and All-Cause, Cancer, and Cardiovascular Mortality Among US Adults Arch Intern Med, February 25, 2008; 168(4): 404 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meplan, L. K. Crosley, F. Nicol, G. J. Beckett, A. F. Howie, K. E. Hill, G. Horgan, J. C. Mathers, J. R. Arthur, and J. E. Hesketh Genetic polymorphisms in the human selenoprotein P gene determine the response of selenoprotein markers to selenium supplementation in a gender-specific manner (the SELGEN study) FASEB J, October 1, 2007; 21(12): 3063 - 3074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lauretani, R. D Semba, S. Bandinelli, A. L Ray, J. M Guralnik, and L. Ferrucci Association of low plasma selenium concentrations with poor muscle strength in older community-dwelling adults: the InCHIANTI Study Am. J. Clinical Nutrition, August 1, 2007; 86(2): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sakr, K. Reinhart, F. Bloos, G. Marx, S. Russwurm, M. Bauer, and F. Brunkhorst Time course and relationship between plasma selenium concentrations, systemic inflammatory response, sepsis, and multiorgan failure Br. J. Anaesth., June 1, 2007; 98(6): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. T. Akbaraly, H. Faure, V. Gourlet, A. Favier, and C. Berr Plasma Carotenoid Levels and Cognitive Performance in an Elderly Population: Results of the EVA Study J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2007; 62(3): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Mathers and J. E. Hesketh The Biological Revolution: Understanding the Impact of SNPs on Diet-Cancer Interrelationships J. Nutr., January 1, 2007; 137(1): 253S - 258S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Flores-Mateo, A. Navas-Acien, R. Pastor-Barriuso, and E. Guallar Selenium and coronary heart disease: a meta-analysis. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 762 - 773. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
